Open access
Jul 2026
Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis.
DLX6 is significantly upregulated in LUAD and offers a potential therapeutic target for sensitizing cisplatin treatment and improving chemotherapy resistance and highlights DLX6 as a key regulator of ferroptosis and cisplatin sensitivity in LUAD.
Zedong Sun, Minmin Zhou, Can Wang et al.
· Cellular Oncology · 0 citations